Height Is Indicator Of Fitness For Past And Primitive Ancestors

Just  a quick thought while I was taking a walk yesterday which the studies and researchers seem to agree with.

Theory

Based on how many mutations can cause bad effects, and how they almost all lead to stunted growth and short stature, it would seem that for our ancient more primitive ancestors , being taller and exhibiting large size may have been the best most obvious indicator of our genetic fitness and health. As for the modern human, it may not be possible for most humans to disassociate away from the belief that there is a link between height and health. 

However there does seem to be an inverse relationships between height and longevity seen in mostly female populations, which the articles below seem to validate. Being a male, there seems to not be not longevity loss when being tall. So is being taller better? Most of the time yes, but not always.


From NPR website HERE….

Measuring A Country’s Health By Its Height

by NANCY SHUTE

October 25, 2010

Tiffani Mundaray has brought her son Wayne for a well-baby visit in the pediatric practice at Howard University Hospital in Washington, D.C. At age 2, he’s 36 1/4 inches tall — in the 90th percentile.

“His growth velocity is very nice. It’s very appropriate for his age,” says Sohail Rana, Wayne’s pediatrician. “He’s growing well.”

Nancy Shute/NPRAt age 2, Wayne Mundaray is 36 1/4 inches tall — and in the 90th percentile.

From the day we’re born, height equals health. Babies are measured to make sure they’re thriving.

But doctors aren’t the only people who look to height as a sign of health.

Economists like John Komlos of the University of Munich in Germany use height to measure the health of entire countries.  “Height is like holding a mirror to society’s well-being,” Komlos says.

And, it turns out, by that standard, the United States isn’t measuring up.

Fallen From The Top

Through most of American history, we’ve been the tallest population on the planet. Americans were two inches taller than the Englishmen they fought in the Revolutionary War, thanks to abundant food and a healthy rural life, far from the disease-ridden cities of Europe.

But we’re no longer at the top. Northern Europeans are now the world’s tallest people, led by the Dutch. The average Dutch man is 6 feet tall, while the average American man maxes out at 5-foot-9.

Height is like holding a mirror to society’s well-being.

– John Komlos, economist at the University of Munich

Good health care and good nutrition during pregnancy and early childhood are two reasons why the Dutch have grown so tall, Komlos says. In addition, the Dutch guarantee equal access to critical resources like prenatal care. That’s not the case in the United States, where 17 percent of the population has no health insurance.

The height of Americans reached a plateau in the 1960s. As a nation,  we have not grown taller but we also have not lost stature. Komlos says groups of people usually don’t lose height unless they’re in the midst of a famine or a war. “It has practically never occurred in peacetime,” he says.

Komlos would know; he was born in Budapest, Hungary, during World War II. And at 5-foot-7, he is shorter than his father, a fact he attributes to his family’s lack of food, as well as the stresses of life during wartime.

Reaching Maximum Potential

Economists are interested in these biological questions about nations because while height is a reflection of health and nutrition, those factors usually result from economic well-being.

The Netherlands: The World’s Tallest (And Healthiest) Country

Their men tower at an average height of 6-foot-1, and their women average 5-foot-8; those impressive figures confirm the Dutch as the tallest people in the world. So serious are the Dutch about height that there’s even a national association representing tall people. According to The New Yorker, the club has serious political clout.

John Komlos’ 2007 study in Social Science Quarterly offers several possible explanations for the good health and stature of the Dutch. One is the country’s “high-quality” medical system and social services, including a public health monitoring program that allows moms to get child nutrition guidance from a pediatrician. Also, the study notes that lower labor-force participation rates among Dutch women means more moms stay at home, possibly allowing them to better care for their young children.

This year, Commonwealth Fund ranked theNetherlands health system No. 1 among industrialized nations. While the Netherlands doesn’t have a government-run health system, it does require everyone to have insurance coverage. In the same survey, the U.S. came in last and had the highest yearly spending per person.

— Whitney Blair Wyckoff

Economic success and height even correlate to some degree on an individual level. Taller people tend to be smarter, and to earn more.

Andreas Schick, a graduate student at Ohio State University in Columbus, is trying to figure out why. He thinks it gets down to the fact that someone who is healthy and well-fed enough to grow tall — or to the individual’s maximum potential genetic height — is also someone who is able to grow a strong, capable brain.

“If you’ve reached your maximum height, that probably means you’ve reached your physical and mental development,” Schick says. “That helps you reach your maximum potential, be that intellectually or socially.”

But the fact that Americans aren’t getting taller means more and more children won’t have the chance to reach their maximum potential, Komlos says.

And that has ramifications for the future. “A population that is not taking care of their children and youth is going to be in difficulties in a generation or two,” he says.

At Howard University Hospital in Washington, D.C., two miles northwest of the White House, Rana says he sees children in difficulty every day. Many of his young patients suffer health problems from obesity — too many empty calories and fat. Others are not getting enough to eat.

“You would be shocked by how many kids go without food in this town,” he says. “What you have to do is go to clinics like ours and ask people: Did you have a meal today?”

 

From the blog Mark Daily’s Apple, a nice fitness and Diet based Blog HERE

The Connection Between Height and Health

Height has historically been regarded as a marker of health and robustness. We seem to implicitly accept that bigger is indeed better, even if we don’t want to admit it. On average, tall people attain more professional success and make more money, the taller presidential candidate almost always wins, and women are more attracted to tall men. On a very visceral level, the taller person is more physically imposing. After all, who would you rather fight – the dude with a long reach raining punches from up high or the shorter guy with stubby arms who has to work his way inside your guard (although Mike Tyson did pretty well for himself with such “limitations”)? And on that note, who would you prefer as a mate – the physically imposing specimen or the shorter, presumably weaker male?

We in the Primal health community are quick to point out that agriculture reduced physical stature. Generally speaking, bone records indicate that Paleolithic (and, to a lesser extent, Mesolithic) humans were taller than humans living immediately after the advent of agriculture. Multiple sources exist, so let’s take a look at a couple of them before moving on:

According to one study on remains of early Europeans, prior to 16,000 BC, European males stood 179 cm tall, or 5’10.5″, and females stood 158 cm, or 5’2″. Between 8,000 to 6,600 BC, average heights had dropped to 166 cm for males. Heights fell even further in Neolithic populations, dropping down to 164 cm for males and 150 cm for females, only reaching and surpassing 170 cm at the end of the 19th century.

Another source found that Paleolithic humans living between 30,000 and 9,000 BC ran almost 5’10″, which is close to the average modern American male’s height. After agriculture was fully adopted, male height dropped to 161 cm, or 5’5.4″. Females went from 166.5 cm to 154.3 cm under the same parameters.

We know these changes to height also reflected worsened health, because with shortness came dental pathologies like caries, plaque, and decay, signs of arrested growth indicating instances of severe malnutrition, and skull abnormalities that stem from iron deficiency. People got shorter, sicker, and less healthy. Height wasn’t a cause of poor health, of course, but it was an indicator.

And that’s where the statistic of height shines – as an indicator. On a large scale, height increases indicate improved nutritional or socioeconomic status, while decreases indicate poor nutrition, famine, war, or economic hardship. Thus, as a population increases in height, it’s safe to assume that its people are either eating better, making more money, or both. If a population shows decreasing height (or stagnation, which the US is showing), we surmise that something is amiss. There exists no better modern day example of height following health than with North and South Korea. Several studies show that South Koreans are taller than their counterparts to the north. Since the two populations are so closely related, genetic differences can’t explain the discrepancy; it’s got to be environment, especially childhood nutrition. North Koreans are famously malnourished, and the height discrepancy between North and South – about three or four inches on average – is similar to the height discrepancy observed between Paleolithic and Neolithic populations.

There are numerous other examples. Up until the late 1800s, Northern Plains Indian tribes were the tallest people in the world, standing over 172 cm (or about 5’8″) and subsisting on a nourishing diet of wild game, fish, berries, and native plants. That height advantage disappeared with reservation life, of course. Fry bread, vegetable oil, sugar, and white flour mixed with extreme stress and economic hardship are poor substitutes for fresh buffalo and open plains. What about Americans, the ones who supplanted the Plains tribes? For most of the past two hundred years, Americans have been the tallest people in the world, until about fifty years ago when height began to stagnate. Today, American males stand around 5’10.5″, but we haven’t grown in decades and other countries have long since passed us. Meanwhile, European and Asian countries have steadily gained on us. The Dutch, whose men stand over 6′ and whose women stand over 5’7″, are now the tallest in the world. American males are ninth tallest and American females are fifteenth, and any regular reader of mine knows that the nutritional situation in America needs a lot of work. It’s no surprise that we’re stagnating while other countries with better nutrition are growing.

And yet for all the concrete links between a population’s height, health, and nutrition (especially childhood nutrition), some researchers have linked “excessive” height to poor health and longevity. Barring the obvious examples of short-lived people with gigantism and other endocrine disorders, there is some evidence that the shorter among us live the longest. Thomas Samaras, a height/health researcher, has authored several papers arguing that bigger is not necessarily better. In one, he reviews human and animal evidence and seems to present a strong argument, but others have argued that Samaras overlooks evidence to the contrary. While Samaras chooses to focus on increased mortality from non smoking-related cancers in the tall, he ignores the bevy of evidence showing that in industrialized nations, taller people enjoy more protection from all-cause mortality, including heart disease, stroke, and respiratory disease.

But what about those centenarians? As Samaras notes, they, along with nonagenarians (between 90 and 99 years old), are on average shorter than the rest of the population. The long-lived Okinawans are famously dimunitive, and it seems like every other Mediterranean centenarian in the news is a spry old lady.

I like one possible explanation for centenarians being shorter and slighter while enjoying better health and longevity: insulin-like growth factor, or IGF-1, a protein produced in the liver and stimulated by growth hormone that induces systemic growth in almost every cell of the body, including muscle, bone, various organs, cartilage, skin, nerves, and lungs. It even affects DNA synthesis and individual cell growth. IGF-1 is perhaps the biggest determinant of height in humans: in infants, IGF-1 correlates strongly with growth, IGF-1 is highest during growth spurts in pre-teens and teens, and higher levels of IGF-1 usually correlate with adult height. Clearly, enough IGF-1 is required for proper musculoskeletal development, but what about too much? Can you have too much IGF-1?

Staffan Lindeberg thinks that excessive serum levels of IGF-1 from diet-induced hyperinsulinemia are causing unhealthy amounts of growth, which manifest as higher rates of cancer and, yes, height, in Western populations. Simply put, Lindeberg agrees that a population’s height is an indicator of health, but only to a point, after which it indicates excessive and potentially problematic levels of IGF-1. There’s probably something to this; female centenarians are more likely to have an IGF-1 receptor mutation that results in elevated serum levels of IGF-1 while reducing IGF-1 receptor activity. In other words, the body was producing more IGF-1 to make up for the lack of receptor activity. This same receptor mutation has been linked to longevity in multiple animal models resulting in higher serum IGF-1 and lower IGF-1 receptor activity – just like in the human centenarians. In male and female offspring of the centenarians, however, only females showed elevated serum levels. Male offspring had similar IGF-1 levels to control males (those with no familial history of longevity). Female offspring were also 2.5 cm shorter than control females; male offspring were of similar height to control males. Perhaps short stature is more beneficial to women?

Maybe so. Gavrilova looked at draft cards filled out by 30 year-old Americans who would eventually grow up to become centenarians and analyzed the differences between the physical stats of those who would eventually grow up to become centenarians and those who didn’t. While obesity (or “stoutness,” as it was called back then) had strong negative links to longevity, height did not. The group of future centenarians was mostly people of medium height. Being soldiers, however, these were exclusively males. According to the IGF-1 receptor mutation study, only in females is the mutation linked to lower heights and greater longevity.

Overall, though? Height is linked to a population’s health and good childhood nutrition. In certain individuals, given certain genetic differences, short stature may indicate the potential for greater longevity, but not on a population-wide scale. Besides – barring pharmaceutical (or cybernetic) interventions, there’s not a whole lot we full-grown adults can do to alter our heights.

Thanks for reading, everyone. Share your thoughts in the comment board.

 

From the PNAS website HERE

Height, health, and development

  1. Angus Deaton 

Author Affiliations


  1. Woodrow Wilson School and Economics Department, 328 Wallace Hall, Princeton University, Princeton, NJ 08544
  1. Edited by Richard A. Easterlin, University of Southern California, Los Angeles, CA, and approved May 2, 2007 (received for review December 22, 2006)

Abstract

Adult height is determined by genetic potential and by net nutrition, the balance between food intake and the demands on it, including the demands of disease, most importantly during early childhood. Historians have made effective use of recorded heights to indicate living standards, in both health and income, for periods where there are few other data. Understanding the determinants of height is also important for understanding health; taller people earn more on average, do better on cognitive tests, and live longer. This paper investigates the environmental determinants of height across 43 developing countries. Unlike in rich countries, where adult height is well predicted by mortality in infancy, there is no consistent relationship across and within countries between adult height on the one hand and childhood mortality or living conditions on the other. In particular, adult African women are taller than is warranted by their low incomes and high childhood mortality, not to mention their mothers’ educational level and reported nutrition. High childhood mortality in Africa is associated with taller adults, which suggests that mortality selection dominates scarring, the opposite of what is found in the rest of the world. The relationship between population heights and income is inconsistent and unreliable, as is the relationship between income and health more generally.

Footnotes

  • E-mail: deaton@princeton.edu
  • Author contributions: A.D. designed research, performed research, analyzed data, and wrote the paper.

  • The author declares no conflict of interest.

  • This article is a PNAS Direct Submission.

 

Molecular Biology, Biochemistry, And Genetics

All Information was copied form Wikipedia articles for Transcription (Genetics), Translation (Genetics), Process of Reverse Transcription, Posttranslational modificationPrimary Structure, DNA Replication, Epigenetics, and DNA Methylation. From the wikipedia article on the “Central Dogma Of Molecular Biology

Central dogma of molecular biology

The central dogma of molecular biology describes the way genetic information is expected to be transferred in a single direction through a biological system. It was first stated by Francis Crick in 1958[1] and re-stated in a Nature paper published in 1970:[2]

Information flow in biological systems

The central dogma of molecular biology deals with the detailed residue-by-residue transfer of sequential information. It states that such information cannot be transferred back from protein to either protein or nucleic acid.

Or, as Marshall Nirenberg said, “DNA makes RNA makes protein.”[3]

To appreciate the significance of the concept, note that Crick had misapplied the term “dogma” in ignorance. In evolutionary or molecular biological theory, either then or subsequently, Crick’s proposal had nothing to do with the correct meaning of “dogma”. He subsequently documented this error in his autobiography.

The dogma is a framework for understanding the transfer of sequence information between sequential information-carrying biopolymers, in the most common or general case, in living organisms. There are 3 major classes of such biopolymers: DNA and RNA (both nucleic acids), and protein. There are 3×3 = 9 conceivable direct transfers of information that can occur between these. The dogma classes these into 3 groups of 3: 3 general transfers (believed to occur normally in most cells), 3 special transfers (known to occur, but only under specific conditions in case of some viruses or in a laboratory), and 3 unknown transfers (believed never to occur). The general transfers describe the normal flow of biological information: DNA can be copied to DNA (DNA replication), DNA information can be copied into mRNA (transcription), and proteins can be synthesized using the information in mRNA as a template (translation).[2]

Biological sequence information

Primary structure

In biochemistry, the Primary structure of a biological molecule is the exact specification of its atomic composition and the chemical bonds connecting those atoms (including stereochemistry). For a typical unbranched, un-crosslinked biopolymer (such as a molecule of DNA, RNA or typical intracellular protein), the primary structure is equivalent to specifying the sequence of its monomeric subunits, e.g., thenucleotide or peptide sequence.

Primary structure is sometimes mistakenly termed primary sequence, but there is no such term, as well as no parallel concept of secondary or tertiary sequence. By convention, the primary structure of a protein is reported starting from the amino-terminal (N) end to the carboxyl-terminal (C) end, while the primary structure of DNA or RNA molecule is reported from the 5′ end to the 3′ end.

The primary structure of a nucleic acid molecule refers to the exact sequence of nucleotides that comprise the whole molecule. Frequently the primary structure encodes motifs that are of functional importance. Some examples of sequence motifs are: the C/D[1] and H/ACA boxes[2] of snoRNAs, Sm binding site found in spliceosomal RNAs such as U1, U2, U4, U5, U6, U12 and U3, the Shine-Dalgarno sequence,[3] the Kozak consensus sequence[4] and the RNA polymerase III terminator.[5]

The biopolymers that comprise DNA, RNA and amino acids are linear polymers (i.e.: each monomer is connected to at most two other monomers). The sequence of their monomers effectively encodes information. The transfers of information described by the central dogma are faithful, deterministic transfers, wherein one biopolymer’s sequence is used as a template for the construction of another biopolymer with a sequence that is entirely dependent on the original biopolymer’s sequence.

General transfers of biological sequential information

Cdmb.svg

Transcription

Central Dogma of Molecular Biochemistry with Enzymes.jpg

Transcription (genetics)

From Wikipedia, the free encyclopedia

Transcription is the process of creating a complementary RNA copy of a sequence of DNA.[1] Both RNA and DNA are nucleic acids, which use base pairs of nucleotides as a complementary language that can be converted back and forth from DNA to RNA by the action of the correct enzymes. During transcription, a DNA sequence is read by an RNA polymerase, which produces a complementary, antiparallel RNA strand. As opposed to DNA replication, transcription results in an RNA complement that includes uracil (U) in all instances where thymine (T) would have occurred in a DNA complement. Also unlike DNA replication where DNA is synthesised, transcription does not involve an RNA primer to initiate RNA synthesis.

Transcription is explained easily in 4 or 5 steps, each moving like a wave along the DNA.

  1. RNA polymerase moves the transcription bubble, a stretch of unpaired nucleotides, by breaking the hydrogen bonds between complementary nucleotides.
  2. RNA polymerase adds matching RNA nucleotides that are paired with complementary DNA bases.
  3. RNA sugar-phosphate backbone forms with assistance from RNA polymerase.
  4. Hydrogen bonds of the untwisted RNA + DNA helix break, freeing the newly synthesized RNA strand.
  5. If the cell has a nucleus, the RNA is further processed (addition of a 3′ poly-A tail and a 5′ cap) and exits through to the cytoplasm through the nuclear pore complex.

Transcription is the first step leading to gene expression. The stretch of DNA transcribed into an RNA molecule is called a transcription unit and encodes at least one gene. If the gene transcribed encodes aprotein, the result of transcription is messenger RNA (mRNA), which will then be used to create that protein via the process of translation. Alternatively, the transcribed gene may encode for either non-coding RNA genes (such as microRNA, lincRNA, etc.) or ribosomal RNA (rRNA) or transfer RNA (tRNA), other components of the protein-assembly process, or other ribozymes.[2]

A DNA transcription unit encoding for a protein contains not only the sequence that will eventually be directly translated into the protein (the coding sequence) but also regulatory sequences that direct and regulate the synthesis of that protein. The regulatory sequence before (upstream from) the coding sequence is called the five prime untranslated region (5’UTR), and the sequence following (downstream from) the coding sequence is called the three prime untranslated region (3’UTR).[2]

Transcription has some proofreading mechanisms, but they are fewer and less effective than the controls for copying DNA; therefore, transcription has a lower copying fidelity than DNA replication.[3]

As in DNA replication, DNA is read from 3′ → 5′ during transcription. Meanwhile, the complementary RNA is created from the 5′ → 3′ direction. This means its 5′ end is created first in base pairing. Although DNA is arranged as two antiparallel strands in a double helix, only one of the two DNA strands, called the template strand, is used for transcription. This is because RNA is only single-stranded, as opposed to double-stranded DNA. The other DNA strand is called the coding (lagging) strand, because its sequence is the same as the newly created RNA transcript (except for the substitution of uracil for thymine). The use of only the 3′ → 5′ strand eliminates the need for the Okazaki fragments seen in DNA replication.[2]

Transcription is divided into 5 stages: pre-initiationinitiationpromoter clearanceelongation and termination.[2]

Major steps

Stage I: Pre-initiation

In eukaryotes, RNA polymerase, and therefore the initiation of transcription, requires the presence of a core promoter sequence in the DNA. Promoters are regions of DNA that promote transcription and, in eukaryotes, are found at -30, -75, and -90 base pairs upstream from the transcription start site (abbreviated to TSS). Core promoters are sequences within the promoter that are essential for transcription initiation. RNA polymerase is able to bind to core promoters in the presence of various specific transcription factors.[citation needed]

The most characterized type of core promoter in eukaryotes is a short DNA sequence known as a TATA box, found 25-30 base pairs upstream from the TSS.[citation needed] The TATA box, as a core promoter, is the binding site for a transcription factor known as TATA-binding protein (TBP), which is itself a subunit of another transcription factor, called Transcription Factor II D (TFIID). After TFIID binds to the TATA box via the TBP, five more transcription factors and RNA polymerase combine around the TATA box in a series of stages to form a preinitiation complex. One transcription factor, Transcription factor II H, has two components with helicase activity and so is involved in the separating of opposing strands of double-stranded DNA to form the initial transcription bubble. However, only a low, or basal, rate of transcription is driven by the preinitiation complex alone. Other proteins known as activators and repressors, along with any associated coactivators or corepressors, are responsible for modulating transcription rate.[citation needed]

Thus, preinitiation complex contains:[citation needed] 1. Core Promoter Sequence 2. Transcription Factors 3. RNA Polymerase 4. Activators and Repressors. The transcription preinitiation in archaea is, in essence, homologous to that of eukaryotes, but is much less complex.[4] The archaeal preinitiation complex assembles at a TATA-box binding site; however, in archaea, this complex is composed of only RNA polymerase II, TBP, and TFB (the archaeal homologue of eukaryotic transcription factor II B (TFIIB)).[5][6]

Stage II: Initiation

In bacteria, transcription begins with the binding of RNA polymerase to the promoter in DNA. RNA polymerase is a core enzymeconsisting of five subunits: 2 α subunits, 1 β subunit, 1 β’ subunit, and 1 ω subunit. At the start of initiation, the core enzyme is associated with a sigma factor that aids in finding the appropriate -35 and -10 base pairs downstream of promoter sequences.[7] When the sigma factor and RNA polymerase combine, they form a holoenzyme.

Transcription initiation is more complex in eukaryotes. Eukaryotic RNA polymerase does not directly recognize the core promoter sequences. Instead, a collection of proteins called transcription factors mediate the binding of RNA polymerase and the initiation of transcription. Only after certain transcription factors are attached to the promoter does the RNA polymerase bind to it. The completed assembly of transcription factors and RNA polymerase bind to the promoter, forming a transcription initiation complex. Transcription in the archaea domain is similar to transcription in eukaryotes.[8]

Stage III: Promoter clearance

After the first bond is synthesized, the RNA polymerase must clear the promoter. During this time there is a tendency to release the RNA transcript and produce truncated transcripts. This is called abortive initiation and is common for both eukaryotes and prokaryotes.[9] Abortive initiation continues to occur until the σ factor rearranges, resulting in the transcription elongation complex (which gives a 35 bp moving footprint). The σ factor is released before 80 nucleotides of mRNA are synthesized.[10] Once the transcript reaches approximately 23 nucleotides, it no longer slips and elongation can occur. This, like most of the remainder of transcription, is an energy-dependent process, consuming adenosine triphosphate (ATP).[citation needed]

Promoter clearance coincides with phosphorylation of serine 5 on the carboxy terminal domain of RNAP II in eukaryotes, which is phosphorylated by TFIIH.[citation needed]

Stage IV: Elongation

One strand of the DNA, the template strand (or noncoding strand), is used as a template for RNA synthesis. As transcription proceeds, RNA polymerase traverses the template strand and uses base pairing complementarity with the DNA template to create an RNA copy. Although RNA polymerase traverses the template strand from 3′ → 5′, the coding (non-template) strand and newly-formed RNA can also be used as reference points, so transcription can be described as occurring 5′ → 3′. This produces an RNA molecule from 5′ → 3′, an exact copy of the coding strand (except that thymines are replaced with uracils, and the nucleotides are composed of a ribose (5-carbon) sugar where DNA has deoxyribose (one less oxygen atom) in its sugar-phosphate backbone).[citation needed]

Unlike DNA replication, mRNA transcription can involve multiple RNA polymerases on a single DNA template and multiple rounds of transcription (amplification of particular mRNA), so many mRNA molecules can be rapidly produced from a single copy of a gene.[citation needed]

Elongation also involves a proofreading mechanism that can replace incorrectly incorporated bases. In eukaryotes, this may correspond with short pauses during transcription that allow appropriate RNA editing factors to bind. These pauses may be intrinsic to the RNA polymerase or due to chromatin structure.[citation needed]

Stage V: Termination

Bacteria use two different strategies for transcription termination.1.Rho-independent transcription 2.Rho-dependent transcription. In Rho-independent transcription termination,also called intrinsic termination, RNA transcription stops when the newly synthesized RNA molecule forms a G-C-rich hairpin loop followed by a run of Us. When the hairpin forms, the mechanical stress breaks the weak rU-dA bonds, now filling the DNA-RNA hybrid. This pulls the poly-U transcript out of the active site of the RNA polymerase, in effect, terminating transcription. In the “Rho-dependent” type of termination, a protein factor called “Rho” destabilizes the interaction between the template and the mRNA, thus releasing the newly synthesized mRNA from the elongation complex.[11]

Transcription termination in eukaryotes is less understood but involves cleavage of the new transcript followed by template-independent addition of As at its new 3′ end, in a process called polyadenylation.[12]

Transcription is the process by which the information contained in a section of DNA is transferred to a newly assembled piece of messenger RNA (mRNA). It is facilitated by RNA polymerase and transcription factors. In eukaryotic cells the primary transcript (pre-mRNA) must be processed further in order to ensure translation. This normally includes a 5′ cap, a poly-A tail and splicing. Alternative splicing can also occur, which contributes to the diversity of proteins any single mRNA can produce.

Translation (biology and/or genetics)

In molecular biology and genetics, translation is the third stage of protein biosynthesis (part of the overall process of gene expression). In translation, messenger RNA (mRNA) produced by transcription is decoded by the ribosome to produce a specific amino acid chain, or polypeptide, that will later fold into an active protein. In Bacteria, translation occurs in the cell’s cytoplasm, where the large and small subunits of the ribosome are located, and bind to the mRNA. In Eukaryotes, translation occurs across the membrane of the endoplasmic reticulum in a process called vectorial synthesis. The ribosome facilitates decoding by inducing the binding of tRNAswith complementary anticodon sequences to that of the mRNA. The tRNAs carry specific amino acids that are chained together into a polypeptide as the mRNA passes through and is “read” by the ribosome in a fashion reminiscent to that of a stock ticker and ticker tape.

In many instances, the entire ribosome/mRNA complex bind to the outer membrane of the rough endoplasmic reticulum and release the nascent protein polypeptide inside for later vesicle transport and secretion outside of the cell. Many types of transcribed RNA, such as transfer RNA, ribosomal RNA, and small nuclear RNA, do not undergo translation into proteins.

Translation proceeds in four phases: initiationelongationtranslocation and termination (all describing the growth of the amino acid chain, or polypeptide that is the product of translation). Amino acids are brought to ribosomes and assembled into proteins.

In activation, the correct amino acid is covalently bonded to the correct transfer RNA (tRNA). The amino acid is joined by its carboxyl group to the 3′ OH of the tRNA by an ester bond. When the tRNA has an amino acid linked to it, it is termed “charged”. Initiation involves the small subunit of the ribosome binding to the 5′ end of mRNA with the help of initiation factors (IF). Termination of the polypeptide happens when the A site of the ribosome faces a stop codon (UAA, UAG, or UGA). No tRNA can recognize or bind to this codon. Instead, the stop codon induces the binding of arelease factor protein that prompts the disassembly of the entire ribosome/mRNA complex.

A number of antibiotics act by inhibiting translation; these include anisomycin, cycloheximide, chloramphenicol, tetracycline, streptomycin, erythromycin, and puromycin, among others. Prokaryotic ribosomes have a different structure from that of eukaryotic ribosomes, and thus antibiotics can specifically target bacterial infections without any detriment to a eukaryotic host’s cells.

Basic mechanisms

A ribosome translating a protein that is secreted into the endoplasmic reticulum. tRNAs are colored dark blue.

Tertiary structure of tRNA. CCA tail in orange, Acceptor stem in purple, D arm in red, Anticodon arm in blue with Anticodon in black, T arm in green.

The basic process of protein production is addition of one amino acid at a time to the end of a protein. This operation is performed by a ribosome. The choice of amino acid type to add is determined by an mRNA molecule. Each amino acid added is matched to a three nucleotide subsequence of the mRNA. For each such triplet possible, only one particular amino acid type is accepted. The successive amino acids added to the chain are matched to successive nucleotide triplets in the mRNA. In this way the sequence of nucleotides in the template mRNA chain determines the sequence of amino acids in the generated amino acid chain.[1]Addition of an amino acid occurs at the C-terminus of the peptide and thus translation is said to be amino-to-carboxyl directed.[2]

The mRNA carries genetic information encoded as a ribonucleotide sequence from the chromosomes to the ribosomes. The ribonucleotides are “read” by translational machinery in a sequence of nucleotide triplets called codons. Each of those triplets codes for a specific amino acid.

The ribosome molecules translate this code to a specific sequence of amino acids. The ribosome is a multisubunit structure containing rRNA and proteins. It is the “factory” where amino acids are assembled into proteins. tRNAs are small noncoding RNA chains (74-93 nucleotides) that transport amino acids to the ribosome. tRNAs have a site for amino acid attachment, and a site called an anticodon. The anticodon is an RNA triplet complementary to the mRNA triplet that codes for their cargo amino acid.

Aminoacyl tRNA synthetase (an enzyme) catalyzes the bonding between specific tRNAs and the amino acids that their anticodon sequences call for. The product of this reaction is an aminoacyl-tRNA molecule. This aminoacyl-tRNA travels inside the ribosome, where mRNA codons are matched through complementary base pairing to specific tRNA anticodons. The ribosome has three sites for tRNA to bind. They are the aminoacyl site (abbreviated A), the peptidyl site (abbreviated P) and the exit site (abbreviated E). With respect to the mRNA, the three sites are oriented 5’to 3’ E-P-A, because ribosomes moves toward the 3′ end of mRNA. The A site binds the incoming tRNA with the complementary codon on the mRNA. The P site holds the tRNA with the growing polypeptide chain. The E site holds the tRNA without its amino acid. When an aminoacyl-tRNA initially binds to its corresponding codon on the mRNA, it is in the A site. Then, a peptide bond forms between the amino acid of the tRNA in the A site and the amino acid of the charged tRNA in the P site. The growing polypeptide chain is transferred to the tRNA in the A site. Translocation occurs, moving the tRNA in the P site, now without an amino acid, to the E site; the tRNA that was in the A site, now charged with the polypeptide chain, is moved to the P site. The tRNA in the E site leaves and another aminoacyl-tRNA enters the A site to repeat the process.[3]

After the new amino acid is added to the chain, the energy provided by the hydrolysis of a GTP bound to the translocase EF-G (in prokaryotes) and eEF-2 (ineukaryotes) moves the ribosome down one codon towards the 3′ end. The energy required for translation of proteins is significant. For a protein containing n amino acids, the number of high-energy Phosphate bonds required to translate it is 4n-1[citation needed]. The rate of translation varies; it is significantly higher in prokaryotic cells (up to 17-21 amino acid residues per second) than in eukaryotic cells (up to 6-9 amino acid residues per second).[4]

Eventually, this mature mRNA finds its way to a ribosome, where it is translated. In prokaryotic cells, which have no nuclear compartment, the process of transcription and translation may be linked together. In eukaryotic cells, the site of transcription (the cell nucleus) is usually separated from the site of translation (the cytoplasm), so the mRNA must be transported out of the nucleus into the cytoplasm, where it can be bound by ribosomes. The mRNA is read by the ribosome as triplet codons, usually beginning with an AUG (adenine−uracil−guanine), or initiator methionine codon downstream of the ribosome binding site. Complexes of initiation factors and elongation factors bring aminoacylated transfer RNAs (tRNAs) into the ribosome-mRNA complex, matching the codon in the mRNA to the anti-codon on the tRNA, thereby adding the correct amino acid in the sequence encoding the gene. As the amino acids are linked into the growing peptide chain, they begin folding into the correct conformation. Translation ends with a UAA, UGA, or UAG stop codon. The nascent polypeptide chain is then released from the ribosome as a mature protein. In some cases the new polypeptide chain requires additional processing to make a mature protein. The correct folding process is quite complex and may require other proteins, called chaperone proteins. Occasionally, proteins themselves can be further spliced; when this happens, the inside “discarded” section is known as an intein.

DNA replication

DNA replication is a biological process that occurs in all living organisms and copies their DNA; it is the basis for biological inheritance. The process starts when one double-stranded DNA molecule produces two identical copies of the molecule. The cell cycle (mitosis) also pertains to the DNA replication/reproduction process. The cell cycle includes interphase, prophase, metaphase, anaphase, and telophase. Each strand of the original double-stranded DNA molecule serves as template for the production of the complementary strand, a process referred to as semiconservative replication. Cellular proofreading and error toe-checking mechanisms ensure near perfect fidelity for DNA replication.[1][2]

In a cell, DNA replication begins at specific locations in the genome, called “origins”.[3] Unwinding of DNA at the origin, and synthesis of new strands, forms a replication fork. In addition to DNA polymerase, the enzyme that synthesizes the new DNA by adding nucleotides matched to the template strand, a number of other proteins are associated with the fork and assist in the initiation and continuation of DNA synthesis.

DNA replication can also be performed in vitro (artificially, outside a cell). DNA polymerases, isolated from cells, and artificial DNA primers are used to initiate DNA synthesis at known sequences in a template molecule. The polymerase chain reaction (PCR), a common laboratory technique, employs such artificial synthesis in a cyclic manner to amplify a specific target DNA fragment from a pool of DNA.

DNA structure

DNA usually exists as a double-stranded structure, with both strands coiled together to form the characteristic double-helix. Each single strand of DNA is a chain of four types of nucleotides having the bases:adenine, cytosine, guanine, and thymine (commonly noted as A,C, G & T). A nucleotide is a mono-, di-, or triphosphate deoxyribonucleoside; that is, a deoxyribose sugar is attached to one, two, or three phosphates, and a base. Chemical interaction of these nucleotides forms phosphodiester linkages, creating the phosphate-deoxyribose backbone of the DNA double helix with the bases pointing inward. Nucleotides (bases) are matched between strands through hydrogen bonds to form base pairs. Adenine pairs with thymine (two hydrogen bonds), and cytosine pairs with guanine (three hydrogen bonds) because a purine must pair with a pyrimidine: a pyrimidine cannot pair with another pyrimidine because the strands would be very close to each other; in a purine pair, the strands would be too far apart and the structure would be unstable. If A-C paired, there would be one hydrogen not bound to anything, making the DNA unstable.

DNA strands have a directionality, and the different ends of a single strand are called the “3′ (three-prime) end” and the “5′ (five-prime) end” with the direction of the naming going 5 prime to the 3 prime region. The strands of the helix are anti-parallel with one being 5 prime to 3 then the opposite strand 3 prime to 5. These terms refer to the carbon atom in deoxyribose to which the next phosphate in the chain attaches. Directionality has consequences in DNA synthesis, because DNA polymerase can synthesize DNA in only one direction by adding nucleotides to the 3′ end of a DNA strand.

The pairing of bases in DNA through hydrogen bonding means that the information contained within each strand is redundant. The nucleotides on a single strand can be used to reconstruct nucleotides on a newly synthesized partner strand.[4]

DNA polymerase

DNA polymerases adds nucleotides to the 3′ end of a strand of DNA.[5] If a mismatch is accidentally incorporated, the polymerase is inhibited from further extension. Proofreading removes the mismatched nucleotide and extension continues.

DNA polymerases are a family of enzymes that carry out all forms of DNA replication.[6] However, a DNA polymerase can only extend an existing DNA strand paired with a template strand; it cannot begin the synthesis of a new strand. To begin synthesis, a short fragment of DNA or RNA, called a primer, must be created and paired with the template DNA strand.

DNA polymerase then synthesizes a new strand of DNA by extending the 3′ end of an existing nucleotide chain, adding new nucleotides matched to the template strand one at a time via the creation of phosphodiester bonds. The energy for this process of DNA polymerization comes from two of the three total phosphates attached to each unincorporated base. (Free bases with their attached phosphate groups are called nucleoside triphosphates.) When a nucleotide is being added to a growing DNA strand, two of the phosphates are removed and the energy produced creates a phosphodiester bond that attaches the remaining phosphate to the growing chain. The energetics of this process also help explain the directionality of synthesis – if DNA were synthesized in the 3′ to 5′ direction, the energy for the process would come from the 5′ end of the growing strand rather than from free nucleotides.

In general, DNA polymerases are extremely accurate, making less than one mistake for every 107 nucleotides added.[7] Even so, some DNA polymerases also have proofreading ability; they can remove nucleotides from the end of a strand in order to correct mismatched bases. If the 5′ nucleotide needs to be removed during proofreading, the triphosphate end is lost. Hence, the energy source that usually provides energy to add a new nucleotide is also lost.

Replication process

Main articles: Prokaryotic DNA replication and Eukaryotic DNA replication

DNA Replication, like all biological polymerization processes, proceeds in three enzymatically catalyzed and coordinated steps: initiation, elongation and termination.

Origins

For a cell to divide, it must first replicate its DNA.[8] This process is initiated at particular points in the DNA, known as “origins”, which are targeted by proteins that separate the two strands and initiate DNA synthesis.[3] Origins contain DNA sequences recognized by replication initiator proteins (e.g., DnaA in E. coli’ and the Origin Recognition Complex in yeast).[9] These initiators recruit other proteins to separate the strands and initiate replication forks.

Initiator proteins recruit other proteins and form the pre-replication complex, which separate the DNA strands at the origin and forms a bubble. Origins tend to be “AT-rich” (rich in adenine and thymine bases) to assist this process, because A-T base pairs have two hydrogen bonds (rather than the three formed in a C-G pair)—in general, strands rich in these nucleotides are easier to separate since less energy is required to break relatively fewer hydrogen bonds.[10]

All known DNA replication systems require a free 3′ OH group before synthesis can be initiated (Important note: DNA is read in 3′ to 5′ direction whereas a new strand is synthesised in the 5′ to 3′ direction – this is entirely logical but is often confused). Four distinct mechanisms for synthesis have been described.

1. All cellular life forms and many DNA viruses, phages and plasmids use a primase to synthesize a short RNA primer with a free 3′ OH group which is subsequently elongated by a DNA polymerase.

2. The retroelements (including retroviruses) employ a transfer RNA that primes DNA replication by providing a free 3′ OH that is used for elongation by thereverse transcriptase.

3. In the adenoviruses and the φ29 family of bacteriophages, the 3′ OH group is provided by the side chain of an amino acid of the genome attached protein (the terminal protein) to which nucleotides are added by the DNA polymerase to form a new strand.

4. In the single stranded DNA viruses – a group that includes the circoviruses, the geminiviruses, the parvoviruses and others – and also the many phages and plasmids that use the rolling circle replication (RCR) mechanism, the RCR endonuclease creates a nick the genome strand (single stranded viruses) or one of the DNA strands (plasmids). The 5′ end of the nicked strand is transferred to a tyrosine residue on the nuclease and the free 3′ OH group is then used by the DNA polymerase for new strand synthesis.

The best known of these mechanisms is that used by the cellular organisms. In these once the two strands are separated, RNA primers are created on the template strands. To be more specific, the leading strand receives one RNA primer per active origin of replication while the lagging strand receives several; these several fragments of RNA primers found on the lagging strand of DNA are called Okazaki fragments, named after their discoverer. DNA polymerase extends the leading strand in one continuous motion and the lagging strand in a discontinuous motion (due to the Okazaki fragments). RNase removes the RNA fragments used to initiate replication by DNA polymerase, and another DNA Polymerase enters to fill the gaps. When this is complete, a single nick on the leading strand and several nicks on the lagging strand can be found. Ligase works to fill these nicks in, thus completing the newly replicated DNA molecule.

The primase used in this process differs significantly between bacteria and archaea/eukaryotes. Bacteria use a primase belonging to the DnaG protein superfamily which contains a catalytic domain of the TOPRIM fold type. The TOPRIM fold contains an α/β core with four conserved strands in a Rossmann-like topology. This structure is also found in the catalytic domains of topoisomerase Ia, topoisomerase II, the OLD-family nucleases and DNA repair proteins related to the RecR protein.

The primase used by archaea and eukaryotes in contrast contains a highly derived version of the RNA recognition motif (RRM). This primase is structurally similar to many viral RNA dependent RNA polymerases, reverse transcriptases, cyclic nucleotide generating cyclases and DNA polymerases of the A/B/Y families that are involved in DNA replication and repair. All these proteins share a catalytic mechanism of di-metal-ion-mediated nucleotide transfer, whereby two acidic residues located at the end of the first strand and between the second and third strands of the RRM-like unit respectively, chelate two divalent cations.

As DNA synthesis continues, the original DNA strands continue to unwind on each side of the bubble, forming a replication fork with two prongs. In bacteria, which have a single origin of replication on their circular chromosome, this process eventually creates a “theta structure” (resembling the Greek letter theta: θ). In contrast, eukaryotes have longer linear chromosomes and initiate replication at multiple origins within these.[citation needed]

As the final step in the central dogma, DNA replication must occur in order to faithfully transmit genetic material to the progeny of any cell or organism. Replication is carried out by a complex group of proteins called the replisome which consists of a helicase that unwinds the superhelix as well as the double-stranded DNA helix, and DNA polymerase and its associated proteins, which insert new nucleic in a sequence specific manner. This process typically takes place during S phase of the cell cycle.

Special transfers of biological sequential information

Reverse transcription

Unusual flow of information highlighted in green

Process of reverse transcription

Reverse transcriptase creates single-stranded DNA from an RNA template.

In virus species with reverse transcriptase lacking DNA-dependent DNA polymerase activity, creation of double-stranded DNA can possibly be done by host-encoded DNA polymerase δ, mistaking the viral DNA-RNA for a primer and synthesizing a double-stranded DNA by similar mechanism as in primer removal, where the newly synthesized DNA displaces the original RNA template.

The process of reverse transcription is extremely error-prone and it is during this step that mutations may occur. Such mutations may cause drug resistance.

Reverse transcription is the transfer of information from RNA to DNA (the reverse of normal transcription). This is known to occur in the case of retroviruses, such as HIV, as well as in eukaryotes, in the case ofretrotransposons and telomere synthesis.

RNA replication

RNA replication is the copying of one RNA to another. Many viruses replicate this way. The enzymes that copy RNA to new RNA, called RNA-dependent RNA polymerases, are also found in many eukaryotes where they are involved in RNA silencing.[4] RNA editing, in which an RNA sequence is altered by a complex of proteins and a “guide RNA”, could also be considered an RNA-to-RNA transfer.

Direct translation from DNA to protein

Direct translation from DNA to protein has been demonstrated in a cell-free system (i.e. in a test tube), using extracts from E. coli that contained ribosomes, but not intact cells. These cell fragments could express proteins from foreign DNA templates, and neomycin was found to enhance this effect.[5][6]

Transfers of information not explicitly covered in the theory

Posttranslational modification

Main article: Posttranslational modification

Protein amino acid sequence can be edited after translation by various enzymes. This is a case of protein affecting protein sequence, not explicitly covered by the central dogma.

Inteins

Main article: Intein

An intein is a “parasitic” segment of a protein that is able to excise itself from the chain of amino acids as they emerge from the ribosome and rejoin the remaining portions with a peptide bond. This is a case of a protein affecting its own primary sequence encoded originally by the DNA of a gene. Additionally, most inteins contain a homing endonuclease or HEG domain which is capable of finding a copy of the parent gene not containing the intein nucleotide sequence. On contact with the intein-free copy, the HEG domain initiates the DNA double-stranded break repair mechanism. This process causes the intein sequence to be copied from the original source gene to the intein-free gene. This is an example of protein directly editing DNA sequence, as well as increasing the sequence’s heritable propagation.

Methylation

Variation in methylation states of DNA can alter gene expression levels significantly. Methylation variation usually occurs through the action of DNA methylases. When the change is heritable, it is consideredepigenetic. When the change in information status is not heritable, it would be a somatic epitype. The effective information content has been changed by means of the actions of a protein or proteins on DNA, but the primary DNA sequence is not altered.

DNA methylation

DNA methylation is a biochemical process that is important for normal development in higher organisms. It involves the addition of a methyl group to the5 position of the cytosine pyrimidine ring or the number 6 nitrogen of the adenine purine ring (cytosine and adenine are two of the four bases of DNA). This modification can be inherited through cell division.

DNA methylation is a crucial part of normal organismal development and cellular differentiation in higher organisms. DNA methylation stably alters the gene expression pattern in cells such that cells can “remember where they have been” or decrease gene expression; for example, cells programmed to be pancreatic islets during embryonic development remain pancreatic islets throughout the life of the organism without continuing signals telling them that they need to remain islets. DNA methylation is typically removed during zygote formation and re-established through successive cell divisions during development. However, the latest research shows that hydroxylation of methyl groups occurs rather than complete removal of methyl groups in zygote.[1][2] Some methylation modifications that regulate gene expression are inheritable and are referred to as epigenetic regulation.

In addition, DNA methylation suppresses the expression of viral genes and other deleterious elements that have been incorporated into the genome of the host over time. DNA methylation also forms the basis of chromatin structure, which enables cells to form the myriad characteristics necessary for multicellular life from a single immutable sequence of DNA. DNA methylation also plays a crucial role in the development of nearly all types of cancer.[3]

DNA methylation at the 5 position of cytosine has the specific effect of reducing gene expression and has been found in every vertebrate examined. In adult somatic tissues, DNA methylation typically occurs in a CpG dinucleotide context; non-CpG methylation is prevalent in embryonic stem cells.[4][5][6

DNA methylation is essential for normal development and is associated with a number of key processes including genomic imprinting, X-chromosome inactivation, suppression of repetitive elements, and carcinogenesis.In mammals

Between 60% and 90% of all CpGs are methylated in mammals.[7][8] Methylated C residues spontaneously deaminate to form T residues over evolutionary time; hence CpG dinucleotides steadily mutate to TpG dinucleotides, which is evidenced by the under-representation of CpG dinucleotides in the human genome (they occur at only 21% of the expected frequency).[9] (On the other hand, spontaneous deamination of unmethylated C residues gives rise to U residues, a mutation that is quickly recognized and repaired by the cell.)

Unmethylated CpGs are often grouped in clusters called CpG islands, which are present in the 5′ regulatory regions of many genes. In many disease processes, such as cancer, gene promoter CpG islandsacquire abnormal hypermethylation, which results in transcriptional silencing that can be inherited by daughter cells following cell division. Alterations of DNA methylation have been recognized as an important component of cancer development. Hypomethylation, in general, arises earlier and is linked to chromosomal instability and loss of imprinting, whereas hypermethylation is associated with promoters and can arise secondary to gene (oncogene suppressor) silencing, but might be a target for epigenetic therapy.[10]

DNA methylation may affect the transcription of genes in two ways. First, the methylation of DNA itself may physically impede the binding of transcriptional proteins to the gene, and second, and likely more important, methylated DNA may be bound by proteins known as methyl-CpG-binding domain proteins (MBDs). MBD proteins then recruit additional proteins to the locus, such as histone deacetylases and otherchromatin remodeling proteins that can modify histones, thereby forming compact, inactive chromatin, termed heterochromatin. This link between DNA methylation and chromatin structure is very important. In particular, loss of methyl-CpG-binding protein 2 (MeCP2) has been implicated in Rett syndrome; and methyl-CpG-binding domain protein 2 (MBD2) mediates the transcriptional silencing of hypermethylated genes in cancer.

Research has suggested that long-term memory storage in humans may be regulated by DNA methylation.[11][12]

In cancer

DNA methylation is an important regulator of gene transcription and a large body of evidence has demonstrated that genes with high levels of 5-methylcytosine in their promoter region are transcriptionally silent, and that DNA methylation gradually accumulates upon long-term gene silencing. DNA methylation is essential during embryonic development, and in somatic cells, patterns of DNA methylation are generally transmitted to daughter cells with a high fidelity. Aberrant DNA methylation patterns have been associated with a large number of human malignancies and found in two distinct forms: hypermethylation and hypomethylation compared to normal tissue. Hypermethylation typically occurs at CpG islands in the promoter region and is associated with gene inactivation. Global hypomethylation has also been implicated in the development and progression of cancer through different mechanisms.[13]

DNA methyltransferases

In mammalian cells, DNA methylation occurs mainly at the C5 position of CpG dinucleotides and is carried out by two general classes of enzymatic activities – maintenance methylation and de novomethylation.[citation needed]

Maintenance methylation activity is necessary to preserve DNA methylation after every cellular DNA replication cycle. Without the DNA methyltransferase (DNMT), the replication machinery itself would produce daughter strands that are unmethylated and, over time, would lead to passive demethylation. DNMT1 is the proposed maintenance methyltransferase that is responsible for copying DNA methylation patterns to the daughter strands during DNA replication. Mouse models with both copies of DNMT1 deleted are embryonic lethal at approximately day 9, due to the requirement of DNMT1 activity for development in mammalian cells.

It is thought that DNMT3a and DNMT3b are the de novo methyltransferases that set up DNA methylation patterns early in development. DNMT3L is a protein that is homologous to the other DNMT3s but has no catalytic activity. Instead, DNMT3L assists the de novo methyltransferases by increasing their ability to bind to DNA and stimulating their activity. Finally, DNMT2 (TRDMT1) has been identified as a DNA methyltransferase homolog, containing all 10 sequence motifs common to all DNA methyltransferases; however, DNMT2 (TRDMT1) does not methylate DNA but instead methylates cytosine-38 in the anticodon loop of aspartic acid transfer RNA.[14]

Since many tumor suppressor genes are silenced by DNA methylation during carcinogenesis, there have been attempts to re-express these genes by inhibiting the DNMTs. 5-Aza-2′-deoxycytidine (decitabine) is a nucleoside analog that inhibits DNMTs by trapping them in a covalent complex on DNA by preventing the β-elimination step of catalysis, thus resulting in the enzymes’ degradation. However, for decitabine to be active, it must be incorporated into the genome of the cell, which can cause mutations in the daughter cells if the cell does not die. In addition, decitabine is toxic to the bone marrow, which limits the size of its therapeutic window. These pitfalls have led to the development of antisense RNA therapies that target the DNMTs by degrading their mRNAs and preventing their translation. However, it is currently unclear whether targeting DNMT1 alone is sufficient to reactivate tumor suppressor genes silenced by DNA methylation.

Epigenetics

For the unfolding of an organism or the theory that plants and animals (including humans) develop in this way, see epigenesis (biology). For epigenetics in robotics, see developmental robotics.

In biology, and specifically genetics, epigenetics is the study of heritable changes in gene expression or cellular phenotype caused by mechanisms other than changes in the underlying DNA sequence – hence the name epi- (Greek: επί– over, above, outer) -genetics. It refers to functionally relevant modifications to the genome that do not involve a change in the nucleotide sequence. Examples of such changes areDNA methylation and histone modification, both of which serve to regulate gene expression without altering the underlying DNA sequence.

These changes may remain through cell divisions for the remainder of the cell’s life and may also last for multiple generations. However, there is no change in the underlying DNA sequence of the organism;[1]instead, non-genetic factors cause the organism’s genes to behave (or “express themselves”) differently.[2]

One example of epigenetic changes in eukaryotic biology is the process of cellular differentiation. During morphogenesis, totipotent stem cells become the various pluripotent cell lines of the embryo, which in turn become fully differentiated cells. In other words, a single fertilized egg cell – the zygote – changes into the many cell types including neurons, muscle cells, epithelium, endothelium of blood vessels, etc. as it continues to divide. It does so by activating some genes while inhibiting others.[3]

In 2011, it was demonstrated that the methylation of mRNA has a critical role in human energy homeostasis. The obesity associated FTO gene is shown to be able to demethylate N6-methyladenosine in RNA. This opened the related field of RNA epigenetics.[4][5]

Etymology and definitions

Epigenetics (as in “epigenetic landscape”) was coined by C. H. Waddington in 1942 as a portmanteau of the words genetics and epigenesis.[6]Epigenesis is an old[7] word that has more recently been used (see preformationism for historical background) to describe the differentiation of cells from their initial totipotent state in embryonic development. When Waddington coined the term the physical nature of genes and their role in heredity was not known; he used it as a conceptual model of how genes might interact with their surroundings to produce a phenotype.

Robin Holliday defined epigenetics as “the study of the mechanisms of temporal and spatial control of gene activity during the development of complex organisms.”[8] Thus epigenetic can be used to describe anything other than DNA sequence that influences the development of an organism.

The modern usage of the word in scientific discourse is more narrow, referring to heritable traits (over rounds of cell division and sometimes transgenerationally) that do not involve changes to the underlying DNA sequence.[9] The Greek prefix epi- in epigenetics implies features that are “on top of” or “in addition to” genetics; thus epigenetic traits exist on top of or in addition to the traditional molecular basis for inheritance.

The similarity of the word to “genetics” has generated many parallel usages. The “epigenome” is a parallel to the word “genome”, and refers to the overall epigenetic state of a cell. The phrase “genetic code” has also been adapted—the “epigenetic code” has been used to describe the set of epigenetic features that create different phenotypes in different cells. Taken to its extreme, the “epigenetic code” could represent the total state of the cell, with the position of each molecule accounted for in an epigenomic map, a diagrammatic representation of the gene expression, DNA methylation and histone modification status of a particular genomic region. More typically, the term is used in reference to systematic efforts to measure specific, relevant forms of epigenetic information such as thehistone code or DNA methylation patterns.

The psychologist Erik Erikson used the term epigenetic in his book Identity: Youth and Crisis (1968). Erikson writes that the epigenetic principle is where “anything that grows has a ground plan, and that out of this ground plan, the parts arise, each part having its time of special ascendancy, until all parts have arisen to form a functioning whole.”[10] That usage, however, is of primarily historical interest.[11]

Molecular basis of epigenetics

Epigenetic changes can modify the activation of certain genes, but not the sequence of DNA. Additionally, the chromatin proteins associated with DNA may be activated or silenced. This is why the differentiated cells in a multi-cellular organism express only the genes that are necessary for their own activity. Epigenetic changes are preserved when cells divide. Most epigenetic changes only occur within the course of one individual organism’s lifetime, but, if gene disactivation occurs in a sperm or egg cell that results in fertilization, then some epigenetic changes can be transferred to the next generation.[12]This raises the question of whether or not epigenetic changes in an organism can alter the basic structure of its DNA (see Evolution, below), a form of Lamarckism.

Specific epigenetic processes include paramutation, bookmarking, imprinting, gene silencing, X chromosome inactivation, position effect, reprogramming, transvection, maternal effects, the progress ofcarcinogenesis, many effects of teratogens, regulation of histone modifications and heterochromatin, and technical limitations affecting parthenogenesis and cloning.

Epigenetic research uses a wide range of molecular biologic techniques to further our understanding of epigenetic phenomena, including chromatin immunoprecipitation (together with its large-scale variantsChIP-on-chip and ChIP-Seq), fluorescent in situ hybridization, methylation-sensitive restriction enzymes, DNA adenine methyltransferase identification (DamID) and bisulfite sequencing. Furthermore, the use ofbioinformatic methods is playing an increasing role (computational epigenetics).

Catch Up Growth Explained, Can We Use It To Increase In Height And Grow Taller?

Me: Once you have been doing enough research on how to increase height and grow taller once type of phenomenon which I heard over and over again was this idea of catch up growth, which often happens in adolescents which went through a strange stage where growth was first slow and inhibited but suddenly accelerated in speed and there was a dramatic increase in height.

It seems that the phenomenon of catch up growth can be explained if we understand the senescence of growth plates. As stated in a very recent post, there has been a lot of experimental evidence that the senescence of growth plates can be partially explained by the idea that the progenitor chondrocytes in the resting zone have a limited replicative capacity which is gradually exhausted with increasing cell division. There are actually a few compounds like gluccocorticoids which not only inhibit the proliferation of chondrocytes, but also decrease the rate of senescence of the growth plates. This means that at the same time that it is keep height shorter, it also is making the  possibility that height can be a lot taller later on. I guess the easy analogy is the tortoise which is slow and steady can often cover more distance than the hare which is fast and easily runs out of steam. Hypothyroidism can also decrease the mechanism of growth plate senescence. 

Using this type of basic background scientific knowledge, we can deduce that the phenomenon of catchup growth is where the senescence of growth plate first slows down while the proliferation of chondorcytes also slows down thus decreasing the longitundinla growth rate. For the young kids or their parent who might be worried and concerned their kids won’t ever grow taller, this might look like the child has finished growing. Then some trigger which is unknown at this time come along, restarts the growth plate senescence mechanism up again, accelerating the speed of growth which will also increase the proliferation rate of the chondrocytes in the resting zone which is the real cause for longitudinal growth. All of sudden ,the kid who might have been short in middle school goes through a crazy sudden growth spurt in high school and they find themselves taller than many of the kids who used to be taller than them.

As stated before in a previous post, I think there may be a way to use the phenomenon of catch up growth, at more specifically the cause of catch up growth, to make height increase possible and get people to grow to be taller than what they were programmed to be originally. We note that gluccocorticoids controls the senescence of the growth plate. Instead of just increasing or decreasing the amount going through the system, which will just slow down the process of growth in both directions, we might be able to create a pulsing action for the gluccocorticoids. The pulsing behavior could mean that a drop in gluccocorticoids than lead to sudden growth spurts from the letting up for the natural senescence of the growth plates, and when the proiferation capacity of the chondrocytes in the resting zone starts to drop, we overwhelm the growth plates with gluccocorticoids thus allowing the chondrocytes to recovery back up their proliferation capacities again. We just repeat this process which is sinusoidal in behavior. Coincidently, I have an unpublished post about using PEMF technology to stimulate the epiphyseal plates using very specific in form and shape of electrical signal generators which have pulsing action. There is a strong signal for a short time, which goes away, only to be repeated at a specific time interval later. I’ll get that post out within the next few days.

I found a nice PubMed abstract that gives an idea on the possible cause for catchup growth which seems to agree with the findings I have researched about recently.

From source link HERE


Endocr Dev. 2011;21:23-9. Epub 2011 Aug 22.

Growth plate senescence and catch-up growth.

Lui JC, Nilsson O, Baron J.

Source

Developmental Endocrinology Branch, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892- 1103, USA.

Abstract

Longitudinal bone growth is rapid in prenatal and early postnatal life, but then slows with age and eventually ceases. This growth deceleration is caused primarily by a decrease in chondrocyte proliferation, and is associated with other structural, functional, and molecular changes collectively termed growth plate senescence. Current evidence suggests that growth plate senescence occurs because the progenitor chondrocytes in the resting zone have a limited replicative capacity which is gradually exhausted with increasing cell division. In addition, recent experimental findings from laboratory and clinical studies suggest that growth plate senescence explains the phenomenon of catch-up growth. Growth-inhibiting conditions such as glucocorticoid excess and hypothyroidism delay the program of growth plate senescence. Consequently, growth plates are less senescent after these conditions resolve and therefore grow more rapidly than is normal for age, resulting in catch-up growth.

Copyright © 2011 S. Karger AG, Basel.

PMID: 21865751    [PubMed – indexed for MEDLINE] 
PMCID:   PMC3420820

The 3 Men Who Lacked Estrogen Receptors Who Did Not Stop Growing

Me: These articles that are posted below are on the 3 male subjects that have been found to issues with their estrogen receptors causing them to have unfused growth plates and grow to extraordinary heights. I feel that this article is one of those posts that the reader should pay more attention to because it can give clues to ideas that can work. The exact location of this gene mutation was at the estrogen receptor or for cytochrome P-450 aromatase. There was a single G →A mutation at base pair (bp) 1094 in exon 9 of the P-450 aromatase gene, resulting in a glutamine instead of an arginine at position 365. For the other subject, his genetic mutation was a variant banding pattern in exon 2. Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon. For the last subjects, who were brother and sister, their genetic mutation was at  only a single human gene encoding aromatase P450 (CYP19) has been isolated; tissue-specific regulation is controlled in part by alternative promoters in a tissue-specific manner. they report a novel mutation in the CYP19 gene.

Endocrinology

Edited by: Thomas W. Durso ‘MAJOR IMPORTANCE’: Eric Smith evaluated a man shown to be estrogen-resistant. E.P. Smith, J. Boyd, G.R. Frank, H. Takahashi, R.M. Cohen, B. Specker, T.C. Williams, D.B. Lubahn, K.S. Korach, “Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man,” New England Journal of Medicine, 331:1056-61, 1994. (Cited in more than 50 publications as of August 1996) Comments by Eric P. Smith, Cincinnati Children’s Hospital Medical Center, University o

October 14, 1996

Edited by: Thomas W. Durso

Estrogen is generally thought to have important effects only on women. But with the publication of this paper, describing the first reported case of estrogen resistance in a human male, researchers demonstrated the importance of the hormone in men.E.P. Smith, J. Boyd, G.R. Frank, H. Takahashi, R.M. Cohen, B. Specker, T.C. Williams, D.B. Lubahn, K.S. Korach, “Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man,” New England Journal of Medicine331:10

The subject of this paper, a 28-year-old man who stood at 6 feet, 8 inches, was experiencing secondary-to-continued growth well into his third decade, and displayed delayed bone-age maturation comparable to a 15- year-old boy. Ultimately, the man was evaluated by pediatric endocrinologist Eric P. Smith, an associate professor of pediatrics at Cincinnati Children’s Hospital Medical Center, which is affiliated with the University of Cincinnati College of Medicine.

Despite the man’s age and height, further testing revealed that he had a bone-mineral mass similar to a “severely osteoporotic elderly woman,” according to Smith. Levels of testosterone and androgen, a pair of male hormones, were normal, but estrogen levels were elevated, which suggested resistance to estrogen.

To test the hypothesis of estrogen resistance, Smith treated the man with estrogen skin patches, raising the hormone level tenfold, for six months. “There was no measurable response to the treatment,” Smith recalls. “A normal individual would develop substantial breast enlargement, among many other physical and biomedical changes. We were quite surprised, because his lack of response suggested severe estrogen resistance, a condition that was thought to be embryonically lethal. Indeed, this was considered to be the explanation for why no cases of loss-of-function estrogen receptor mutations had been reported in the medical literature.”

But Smith was aware of a study in which researchers had successfully bred and sustained mice with mutated estrogen-receptor genes (D.B. Lubahn, Proceedings of the National Academy of Sciences90:11162-6, 1993). He sent samples of the man’s DNA to Kenneth S. Korach, chief of the Laboratory of Reproductive and Developmental Toxicology at the National Institute of Environmental Health Sciences in Research Triangle Park, N.C. Evaluation of the DNA revealed a mutation in the gene encoding the estrogen receptor.The implications of the case are significant, say the researchers. “Here’s the first reported mutation of this gene resulting in a living individual who is hormonally insensitive to estrogen,” Korach states.

The paper demonstrated, “dramatically and unequivocally,” according to Korach, that estrogen is the principal hormone involved in the final fusion of the epiphyses, the plates at the end of bones whose closure is necessary for bones to stop lengthening. In addition, the researchers say, estrogen must now be considered important in males for normal accretion of bone-mineral mass, with major implications for the common clinical condition of osteoporosis.

“Whether you have patients who don’t make estrogen or make estrogen but can’t use it through the receptors,” Korach declares, “you still have the same effect on the skeleton.”

Smith points to estrogen’s involvement in many different processes, such as growth and bone density, and the implications for males as the reasons the paper has been highly cited.

“From my point of view as a pediatric endocrinologist, the major importance is on growth implications,” he says. “We see a lot of children who have growth disorders, and their degree of bone maturation is a major component of their evaluation. Any advance in the understanding of the primary determinants of how growth plates mature and fuse will be useful in the evaluation of childhood growth disorders. Potentially, final height could be augmented by manipulating the androgen/estrogen milieu.”

Korach also attributes interest in the paper to “the uniqueness and novelty of the findings.” He notes that it was the first clinical description of this gene mutation, which debunked the long-held notion that it was a lethal mutation. “Now it turns out you can have mutation in this gene and it does not result in lethality, but produces significant phenotype.”

In addition, Korach points out correlations between the man’s case and the male mice. For example, the estrogen-receptor gene mutation in the mice resulted in male infertility, and Korach speculates that human males may evolve similar impairments related to decreased estrogen action. The man profiled in this paper had a low-normal sperm count with decreased movement at the time of the initial analysis, and Korach explains that the condition in the mice appears progressive.

“It told us for the first time there’s a critical role for estrogen in male fertility, and effects on the male reproductive tract were a real surprise,” he adds. “From the past we thought it was something that was androgen- or testosterone-related. Now we see the lack of a functional estrogen receptor and lack of estrogen action has been associated with male infertility. It ties estrogen exposure to the male, and it’s as important there as it is to the female. We hope it will allow us to make people aware that this mutation can exist in the human population.”

Effect of Testosterone and Estradiol in a Man with Aromatase Deficiency

Cesare Carani, M.D., Kenan Qin, Ph.D., Manuela Simoni, M.D., Ph.D., Marco Faustini-Fustini, M.D., Stefania Serpente, M.D., Jeff Boyd, Ph.D., Kenneth S. Korach, Ph.D., and Evan R. Simpson, Ph.D.

N Engl J Med 1997; 337:91-95  July 10, 1997  DOI: 10.1056/NEJM199707103370204

Recent reports of disruptive mutations of the genes for the estrogen receptor or for cytochrome P-450 aromatase1-6 have shed new light on the role of estrogen. In females the lack of estrogen due to aromatase deficiency leads to pseudohermaphroditism and progressive virilization at puberty, whereas in males pubertal development is normal. In members of both sexes epiphyseal closure is delayed, resulting in a eunuchoid habitus, and osteopenia is present.6 These findings suggest a crucial role of estrogen in skeletal maturation.1-6 We describe the responses to androgen and estrogen in a man with a novel, homozygous inactivating mutation of the P-450 aromatase gene.

CASE REPORT

The proband, the second of 10 siblings, was born after an uncomplicated pregnancy. His parents were first cousins (Figure 1FIGURE 1Pedigree of a Man with Aromatase Deficiency.). The patient’s early growth and pubertal development were normal, although his testicular volume remained subnormal. At 18 years of age he was 170 cm tall (25th percentile), and he continued to grow thereafter. At the age of 28 years, x-ray films of the right arm obtained after an injury revealed unfused epiphyses and osteopenia. At the age of 29 years, he married a woman who did not conceive despite regular unprotected intercourse. Semen analysis one year later7 revealed a sperm count of 1 million per milliliter (normal, >20 million) with 100 percent immotile spermatozoa. The patient was treated with 150 IU of human menopausal gonadotropin and 1000 IU of human chorionic gonadotropin intramuscularly three times weekly for four months, with no change in the sperm count.
In 1988, at the age of 31, the patient was evaluated because of a four-year history of persistent linear growth, infertility, and moderate skeletal pain, especially in the knee, that limited his ability to walk. He weighed 96.5 kg and was 187 cm tall (97th percentile). His arm span was 204 cm, and the ratio of the upper segment to the lower segment was 0.85. Physical examination revealed bilateral genu valgum. The patient’s blood pressure was normal. He had normal optic fundi and no gynecomastia, acromegaly, goiter, or acanthosis nigricans. The volume of each testis was 8 ml. His penis size and pattern of pubic hair were normal. His sexual identity and psychosexual orientation as assessed by questionnaire8 were heterosexual, and his libido was normal. He had spontaneous erections sufficient for intercourse.

The patient had normal concentrations of serum testosterone, undetectable concentrations of estradiol, slightly elevated concentrations of follicle-stimulating hormone, and concentrations of luteinizing hormone at the upper limit of the normal range (Table 1TABLE 1Biochemical Values before and after Six Months of Treatment with Testosterone Enanthate or Transdermal Estradiol in a Man with Aromatase Deficiency.). After he received an intravenous bolus dose of 100 μg of gonadotropin-releasing hormone (GnRH), his serum concentration of luteinizing hormone rose from 6 to 18 IU per liter after 60 minutes (when the peak response occurs), and the concentration of serum follicle-stimulating hormone rose from 14 to 19 IU per liter. The serum concentrations of dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, androstenedione, parathyroid hormone, free thyroxine, and thyrotropin were normal. The serum concentration of growth hormone rose from 0.8 to 6.2 ng per milliliter after the administration of levodopa. The serum concentration of insulin-like growth factor I was 332 ng per milliliter (normal range at the age of 25 to 35 years, 193 to 575). The serum concentrations of total cholesterol and triglycerides were high, and the serum concentration of high-density lipoprotein (HDL) cholesterol was low (Table 1).

X-ray films of the left wrist and hand revealed open metacarpal and phalangeal epiphyses; the bone age was 14.8 years (Figure 2AFIGURE 2X-Ray Films of the Left Hand of the Proband. and Figure 2B). X-ray films of the tibias, knees, and pelvis showed diffuse bone demineralization and lack of epiphyseal fusion. A bone biopsy of the iliac crest after labeling with tetracycline revealed several slightly widened areas of osteoid seams lined by active osteoblasts.

A semen analysis7 revealed a sperm count of less than 1 million per milliliter, with 100 percent immotile spermatozoa. A testicular biopsy showed hypospermatogenesis and germ-cell arrest, mainly at the level of primary spermatocytes. The karyotype was 46,XY.

In an attempt to arrest his persistent linear growth and stimulate epiphyseal closure, the patient, after giving informed consent, was treated with 250 mg of testosterone enanthate intramuscularly every 10 days for 6 months. There were no clinical, behavioral, hormonal, or metabolic changes, except for a small decrease in the serum concentration of HDL cholesterol (Table 1). His bone age did not change, and moderate bone pain persisted. He interrupted the treatment spontaneously in 1989 because of its ineffectiveness and because he believed it was rendering him irretrievably infertile.

In 1995 the patient was 190 cm tall (above the 97th percentile), and his bone age and biochemical values had not changed appreciably (Table 1). The results of an oral glucose-tolerance test were normal. The similarity between his phenotype and that of a man with a mutated estrogen-receptor gene1 prompted us to analyze the patient’s DNA for a mutation in that gene or in the P-450 aromatase gene. As expected from the low serum estradiol levels, the estrogen-receptor gene was normal, but there was a single G →A mutation at base pair (bp) 1094 in exon 9 of the P-450 aromatase gene, resulting in a glutamine instead of an arginine at position 365 (Figure 3FIGURE 3Nucleotide Sequence of a Region of Exon 9 of the P-450 Aromatase Gene in the Patient, a Normal Subject, and the Patient’s Parents.). This mutation abolishes a site cleaved by the restriction enzyme Acc651; restriction analysis, used to determine the carrier status of other family members, showed that both parents were heterozygous for the mutation. Expression studies in COS-1 cells showed that the aromatase activity of the mutant protein was 0.4 percent of that of the wild-type protein in the presence of the same amount of total cellular protein, as measured by a Western blot assay corrected for the efficiency of transfection.

After giving informed consent and with the approval of the local university review board, the patient was treated with 50 μg of transdermal estradiol twice weekly. His bone pain improved after four months and resolved completely after six months. His serum concentrations of luteinizing hormone, follicle–stimulating hormone, and testosterone decreased, that of HDL cholesterol increased, and that of low-density lipoprotein (LDL) cholesterol decreased (Table 1). His fasting concentrations of serum insulin and blood glucose were normal. The serum concentrations of alkaline phosphatase and osteocalcin increased, as did the urinary excretion of pyridinoline, indicating active bone remodeling (Table 1). The bone mineral density of the lumbar spine was 0.93 g per square centimeter before treatment (normal range 9 for adolescents in Tanner stage 5, 0.96 to 1.31) and was 1.05 and 1.17 g per square centimeter after four and seven months of treatment, respectively. Epiphyseal closure was documented after nine months of therapy, with a bone age greater than 16 years (Figure 2A andFigure 2B). The treatment did not induce gynecomastia, hyperprolactinemia, or sexual dysfunction. Testicular volume and the results of semen analysis did not change. At this writing the patient is being treated with 25 μg of transdermal estradiol twice weekly.

METHODS

Biochemical Measurements

Blood samples were obtained by venipuncture after an overnight fast. Serum luteinizing hormone, follicle-stimulating hormone, and growth hormone were measured by an immunofluorimetric assay (Delfia kits, Pharmacia, Milan, Italy) according to the instructions of the manufacturer. All the other hormones were measured by commercially available radioimmunoassays.

Molecular Analysis of the Genes for the Estrogen Receptor and P-450 Aromatase

Genomic DNA was prepared from blood samples obtained from the patient, his parents, two of his brothers, one of his nephews, and a normal unrelated man.4 Single-strand conformation analysis of the estrogen-receptor gene was performed as previously reported.1 To determine the complete sequence of the exons and the intron–exon junctions, each exon of the P-450 aromatase gene, including the 5′ untranslated exons and their respective 5′ flanking regions, was amplified as previously described.10 Both strands were sequenced to exclude artifacts. The complete sequence of each exon, including the 5′ and 3′ splice junctions, was compared with the published sequence.11

Exon 9 of the genomic DNA from the normal subject, the proband, and the family members was amplified and digested with Acc651 (Promega, Madison, Wis.), according to the specifications of the manufacturer, and subjected to electrophoresis in a 2 percent agarose gel. The digested fragments were visualized by staining with ethidium bromide.

P-450 aromatase complementary DNA (cDNA) was prepared from wild-type pCMV5arom.11 The wild-type, mutant (R365Q), and vector-only constructs were transfected into COS-1 cells by lipofectamine (BRL, Grand Island, N.Y.). Aromatase activity was determined by the production of tritiated water from [1β-3H]androstenedione.12 Incubations were conducted in triplicate 48 hours after transfection. Western blot analysis was performed as previously described.10

DISCUSSION

We studied the effects of estrogen therapy in a man with a loss-of-function mutation of the aromatase gene. Our first conclusion is that estrogen therapy had a large effect on the patient’s skeletal growth and bone maturation, whereas androgen therapy did not. The dichotomy between the histologic picture of active bone formation and normal biochemical measures of bone metabolism suggests that testosterone exerted an active effect on osteoblasts, albeit an inefficient one. With estrogen treatment spinal bone mineral density increased, and complete epiphyseal closure was achieved after nine months. The increases in bone mineral density, serum levels of alkaline phosphatase and osteocalcin, and urinary excretion of pyridinoline were similar to those that occur during normal skeletal maturation during puberty.13,14 By contrast, testosterone had no effect on skeletal maturation. Therefore, the eunuchoid skeleton may result mainly from a deficiency of estrogen, rather than a deficiency of androgen. The lack of eunuchoid skeletal development in patients with complete androgen insensitivity supports this view.15 Conversely, patients of either sex who have a complete deficiency of 17α-hydroxylase or a combined deficiency of 17α-hydroxylase and 17,20-lyase have tall stature, retardation of bone age, osteoporosis, and a eunuchoid skeleton16 — a phenotype classically related to the poor production of sex steroids, which can now be explained by a deficiency of estrogen. As is consistent with these findings, estrogen seems required for epiphyseal fusion, an event that takes longer in patients with hypogonadism, who produce insufficient androgens for aromatization. Such fusion never takes place in men with estrogen deficiency or estrogen resistance.

Estrogen treatment induced substantial decreases in the ratio of serum LDL cholesterol to serum HDL cholesterol and in serum triglycerides in our patient (Table 1). Although this effect may depend at least in part on reduced concentrations of serum testosterone, it is clear that the abnormal lipid profile in an aromatase-deficient subject can be modified with estrogen treatment.17

Our patient did not have insulin resistance, unlike previously described patients with aromatase deficiency or estrogen insensitivity.1,4 This finding raises the possibility that insulin resistance is an unrelated phenomenon. His serum concentrations of luteinizing hormone and follicle-stimulating hormone were normal or slightly elevated and responded normally to GnRH stimulation. However, estrogen treatment caused complete suppression of serum gonadotropins whereas androgen treatment did not. In contrast, serum gonadotropins are hyperresponsive to GnRH in female patients with aromatase deficiency,3 because there is a complete absence of steroid feedback. These results indicate that the mechanism of sex-steroid–gonadotropin feedback in male patients is mainly mediated by testosterone, but that some testosterone must be converted to estrogen.17-22 This conclusion is supported by a report that the concomitant administration of testosterone and an aromatase inhibitor prevents testosterone-induced suppression of gonadotropin,20 whereas dihydrotestosterone has no effect.21

Unlike the other two men with estrogen deficiency or resistance described to date, our patient had small testicles and severe oligozoospermia. Azoospermia and infertility were also reported in one of his brothers (Subject IV-5), who had a normal P-450 aromatase gene. Therefore, spermatogenic damage may also be a primary event in the proband, independent of estrogen deficiency. Mouse germ cells express aromatase,23 and mice in which the estrogen-receptor gene is knocked out have reduced testicular volume and are infertile, indicating that estrogen is necessary for fertility in that species.24 In adult men, aromatase is located in Leydig cells, but its function is unknown. 25 The ineffectiveness of estrogen therapy in inducing spermatogenesis in our patient argues against estrogen-dependent spermatogenic damage.

In conclusion, we describe a therapeutic response to estrogen therapy, but not to androgen therapy, in a man with aromatase deficiency. When to initiate treatment, at what doses, and for how long all remain uncertain.

Supported in part by a grant from the Italian Research Council, by a grant (FY96-0428) from the March of Dimes, by a grant (R37-A908174) from the Public Health Service, by a training grant (5-T32-HD07190) from the Public Health Service (to Dr. Qin), by a grant (130/15-1) from the Deutsche Forschungsgemeinschaft (to Dr. Simoni), and by a grant from Ares Serono, Geneva, through the European Academy of Andrology (to Dr. Carani).

We are indebted to Dr. M.G. Ferrari for DNA preparation, to Dr. P. Ballanti and Dr. A. Maiorana for histologic analysis, to Dr. V. Spina for radiologic evaluation, and to Dr. P. Beck-Peccoz for his helpful suggestions.

 

N Engl J Med. 1994 Oct 20;331(16):1056-61.

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS.

Source

Department of Pediatrics, Children’s Hospital Medical Center, University of Cincinnati College of Medicine, OH 45229.

Erratum in

  • N Engl J Med 1995 Jan 12;332(2):131.

Abstract

BACKGROUND AND METHODS:

Mutations in the estrogen-receptor gene have been thought to be lethal. A 28-year-old man whose estrogen resistance was caused by a disruptive mutation in the estrogen-receptor gene underwent studies of pituitary-gonadal function and bone density and received transdermal estrogen for six months. Estrogen-receptor DNA, extracted from lymphocytes, was evaluated by analysis of single-strand-conformation polymorphisms and by direct sequencing.

RESULTS:

The patient was tall (204 cm [80.3 in.]) and had incomplete epiphyseal closure, with a history of continued linear growth into adulthood despite otherwise normal pubertal development. He was normally masculinized and had bilateral axillary acanthosis nigricans. Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal. Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased. Glucose tolerance was impaired, and hyperinsulinemia was present. The bone mineral density of the lumbar spine was 0.745 g per square centimeter, 3.1 SD below the mean for age-matched normal women; there was biochemical evidence of increased bone turnover. The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration. Conformation analysis of his estrogen-receptor gene revealed a variant banding pattern in exon 2. Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon. The patient’s parents were heterozygous carriers of this mutation, and pedigree analysis revealed consanguinity.

CONCLUSIONS:

Disruption of the estrogen receptor in humans need not be lethal. Estrogen is important for bone maturation and mineralization in men as well as women.

 

J Clin Endocrinol Metab. 1995 Dec;80(12):3689-98.

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.

Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K.

Source

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Abstract

The aromatase enzyme complex catalyzes the conversion of androgens to estrogens in a wide variety of tissues, including the ovary, testis, placenta, brain, and adipose tissue. Only a single human gene encoding aromatase P450 (CYP19) has been isolated; tissue-specific regulation is controlled in part by alternative promoters in a tissue-specific manner. We report a novel mutation in the CYP19 gene in a sister and brother. The 28-yr-old XX proband, followed since infancy, exhibited the cardinal features of the aromatase deficiency syndrome as recently defined. She had nonadrenal female pseudohermaphrodism at birth and underwent repair of the external genitalia, including a clitorectomy. At the age of puberty, she developed progressive signs of virilization, pubertal failure with no signs of estrogen action, hypergonadotropic hypogonadism, polycystic ovaries on pelvic sonography, and tall stature. The basal concentrations of plasma testosterone, androstenedione, and 17-hydroxyprogesterone were elevated, whereas plasma estradiol was low. Cyst fluid from the polycystic ovaries had a strikingly abnormal ratio of androstenedione and testosterone to estradiol and estrone. Hormone replacement therapy led to breast development, menses, resolution of ovarian cysts, and suppression of the elevated FSH and LH values. Her adult height is 177.6 cm (+2.5 SD). Her only sibling, an XY male, was studied at 24 yr of age. During both pregnancies, the mother exhibited signs of progressive virilization that regressed postpartum. The height of the brother was 204 cm (+3.7 SD) with eunuchoid skeletal proportions, and the weight was 135.1 kg (+2.1 SD). He was sexually fully mature and had macroorchidism. The plasma concentrations of testosterone (2015 ng/dL), 5 alpha-dihydrotestosterone (125 ng/dL), and androstenedione (335 ng/dL) were elevated; estradiol and estrone levels were less than 7 pg/mL. Plasma FSH and LH concentrations were more than 3 times the mean value. Plasma PRL was low; serum insulin-like growth factor I and GH-binding protein were normal. The bone age was 14 yr at a chronological age of 24 3/12 yr. Striking osteopenia was noted at the wrist. Bone mineral densitometric indexes of the lumbar spine (cancellous bone) and distal radius (cortical bone) were consistent with osteoporosis; the distal radius was -4.7 SD below the mean value for age- and sex-matched normal men; indexes of bone turnover were increased. Hyperinsulinemia, increased serum total and low density lipoprotein cholesterol, and triglycerides and decreased high density lipoprotein cholesterol were detected.(ABSTRACT TRUNCATED AT 400 WORDS)

PMID: 8530621    [PubMed – indexed for MEDLINE]

 

Mechanisms And Pathways Of Growth Failure In Primordial Dwarfism, The Implications Of The Results And Data

My Interpretation: Remember that Yao Ming and Kiran Singh were both born from unusually large women with large wombs. Also note that 2nd and 3rd children tend to be bigger than 1st child. Mother’s mental health also is important, so is her health, and much other stuff. Their length and mass, and size right out of the womb was 40% larger than other kids. If they grew at the same rate as other kids, just from the number of their cells, they were destined to be bigger than other babies. 
Note what is said here…
A) Cell size and cell number determine organism size. Conceptually, body size can be altered through reducing the number of cell divisions or reducing cell size. For example, if during an identical period of development, cells divide only five times out of the usual seven rounds of cell division, this will reduce body volume by 75%. Reducing cell volume to a quarter of normal could similarly reduce body size while maintaining cell number constant. (B) In mammals, body size appears to be predominantly determined by cell number.
Genes Dev. 2011 Oct 1;25(19):2011-24.

Mechanisms and pathways of growth failure in primordial dwarfism.

Klingseisen A, Jackson AP.

Source

MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK.

Abstract

The greatest difference between species is size; however, the developmental mechanisms determining organism growth remain poorly understood. Primordial dwarfism is a group of human single-gene disorders with extreme global growth failure (which includes Seckel syndrome, microcephalic osteodysplastic primordial dwarfism I [MOPD] types I and II, and Meier-Gorlin syndrome). Ten genes have now been identified for microcephalic primordial dwarfism, encoding proteins involved in fundamental cellular processes including genome replication (ORC1 [origin recognition complex 1], ORC4, ORC6, CDT1, and CDC6), DNA damage response (ATR [ataxia-telangiectasia and Rad3-related]), mRNA splicing (U4atac), and centrosome function (CEP152, PCNT, and CPAP). Here, we review the cellular and developmental mechanisms underlying the pathogenesis of these conditions and address whether further study of these genes could provide novel insight into the physiological regulation of organism growth.

PMID:  21979914       [PubMed – indexed for MEDLINE] PMCID: PMC319720
From:
Genes Dev. 2011 October 1; 25(19): 2011–2024.
doi: 10.1101/gad.169037

Figure 1.

Click on image to zoom

An external file that holds a picture, illustration, etc.<br />
Object name is 2011fig1.jpg Object name is 2011fig1.jpg

(A) Cell size and cell number determine organism size. Conceptually, body size can be altered through reducing the number of cell divisions or reducing cell size. For example, if during an identical period of development, cells divide only five times out of the usual seven rounds of cell division, this will reduce body volume by 75%. Reducing cell volume to a quarter of normal could similarly reduce body size while maintaining cell number constant. (B) In mammals, body size appears to be predominantly determined by cell number. There is a 3000-fold difference in body mass between mice (25 g) and humans (70 kg), while volume of cells from similar tissues remains relatively unchanged (Conlon and Raff 1999). (C) Cell number can be increased in mammals through alterations in proliferation kinetics. For instance, transgenic expression of stabilized β-catenin protein enlarges brain size in mice during embryogenesis. Midcoronal sections through the embryonic day 15.5 (E15.5) cerebral cortex from a control mouse embryo (left) and a mouse with the Δ90β-catenin-GFP transgene expressed in neural precursors, resulting in an enlarged brain with increased cerebral cortical surface area and folds resembling sulci and gyri of higher mammals. Bar, 1 mm. (Image from Chenn and Walsh 2002. Reprinted with permission from AAAS.)

From:
Genes Dev. 2011 October 1; 25(19): 2011–2024.
doi: 10.1101/gad.169037
Figure 2.
Click on image to zoom

An external file that holds a picture, illustration, etc.<br />
Object name is 2011fig2.jpg Object name is 2011fig2.jpg

Intracellular signaling pathways regulating growth. PI3K/TOR, Hippo, and MAPK pathways regulate growth by modulating protein translation, cell cycle progression, and apoptosis. Schematic of pathways showing key components. Genes highlighted in red are mutated in human genetic syndromes that manifest growth deficiency or overgrowth. (A) Growth hormone acts systemically through its regulation of IGF-1, which activates phosphotidyl-inosine-3 kinase (PI3K) by binding the IGF-1 receptor (IGF-1R). Subsequent activation of downstream kinases results in increased protein translation and ribosome biosynthesis, leading to cellular growth. The pathway is inhibited by the phosphatase PTEN and integrates multiple other signals, such as nutrient/energy levels, through the master kinase target of rapamycin (TOR). TOR activates the ribosomal S6 kinase and facilitates eIF4E activity to promote translation and transcription initiation. (B) The Hippo pathway restricts growth to control organ size and prevent tissue overgrowth and tumorigenesis. The pathway is currently best defined in Drosophila, where the cell polarity protein Crumbs (Crb) and the protocadherins Fat and Dachsous (Ds) activate Hippo kinase, which in turn activates Warts kinase. The signaling cascade negatively regulates the transcriptional coactivator Yorkie (Yki) by retaining Yki in the cytoplasm. This restricts cell proliferation and promotes cell death, as Yki promotes G1 progression over G0 cell cycle exit through transcriptional up-regulation of Cyclin E (CycE) and the E2F transcription factor. Yki also has an anti-apoptotic effect by inducing inhibitor of apoptosis protein (IAP). The core pathway is conserved in mammals: Mst1/2 (Hippo), Lats (Warts), and Yap (Yki). Homologs to Fat and Ds or the target gene bantam have not yet been identified in mammals. (C) The MAPK (ERK) signaling cascade transduces mitogen signals, driving cellular proliferation by promoting G1-to-S-phase progression (Meloche and Pouysségur 2007). Downstream, ERK kinase activates the proproliferative transcription factors Myc and E2F as well as decreases levels of the cyclin-dependent kinase inhibitors p21 and p27. Rather than being entirely discrete signaling pathways, these three signaling pathways (A–C) overlap; for instance, Akt inhibits Hippo activity, while ERK phosphorylates, and thus activates, TOR.


Mechanisms Limiting Body Growth In Mammals.

Me: The article below suggests that the reason why we have limited body sizes may not be from time but from the fact that the limit on adult body size is imposed by a negative feedback loop. The belief is that the cell proliferation decreases from local gene expressions that down regulate the specific genes that cause organ growth. What is very interesting for me are quotes like…
“Different organs appear to use different types of information to precisely target their adult size. For example, skeletal and cardiac muscle growth are negatively regulated by myostatin, the concentration of which depends on muscle mass itself.”
This means that it is possible for us to model this type of homeostatic feedback behavior mathematically using differential equations. I have done enough chemical reaction and process kinetics modeling to be able to easily model this type of behavior using a graphing software.
The other big quote was…
“In pancreas, organ size appears to be limited by the initial number of progenitor cells, suggesting a mechanism based on cell-cycle counting.” 
This statement agrees with other articles which I have found which show that one of the most critical elements is just to see how much initial cell mass and numbers do you have to start to work with ,assuming that all the cells will function and proliferate at their preprogramed rate. 
The next statement… “also suggest that many of the genes that are down-regulated with age serve to regulate proliferation”. This makes me wonder whether it is a good idea to try using gene therapy or controversial new technology for height increase applications on adults. I have read enough to suggest that for adults, most genes that are being up regulated and down regulated is to regulate and actually decrease growth. It seems to suggest that any growth process what accelerates after full physical maturity is automatically assumed by the bodies’ genetic system to be uncontrollable growth, cancer. The body may be inclined to avoid cancer or any type of accelerating and positive growth at all costs to protect the overall organism. This could mean that it may be impossible with any genetic engineering technology today to increase height without having some really bad side effects. 
It shows that the decrease in the rate of height increase aka growth slows down over time and it is actually not because of the decrease in the amount of IGF-1. As a person slows down in growth, the IGF-1 actually increases in their body, which I would guess is because there are no places in the growth plates for the IGF-1 to interact with. 
Endocr Rev. 2011 Jun;32(3):422-40. doi: 10.1210/er.2011-0001. Epub 2011 Mar 25.

Mechanisms limiting body growth in mammals.

Lui JC, Baron J.

Source

Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

Abstract

Recent studies have begun to provide insight into a long-standing mystery in biology-why body growth in animals is rapid in early life but then progressively slows, thus imposing a limit on adult body size. This growth deceleration in mammals is caused by potent suppression of cell proliferation in multiple tissues and is driven primarily by local, rather than systemic, mechanisms. Recent evidence suggests that this progressive decline in proliferation results from a genetic program that occurs in multiple organs and involves the down-regulation of a large set of growth-promoting genes. This program does not appear to be driven simply by time, but rather depends on growth itself, suggesting that the limit on adult body size is imposed by a negative feedback loop. Different organs appear to use different types of information to precisely target their adult size. For example, skeletal and cardiac muscle growth are negatively regulated by myostatin, the concentration of which depends on muscle mass itself. Liver growth appears to be modulated by bile acid flux, a parameter that reflects organ function. In pancreas, organ size appears to be limited by the initial number of progenitor cells, suggesting a mechanism based on cell-cycle counting. Further elucidation of the fundamental mechanisms suppressing juvenile growth is likely to yield important insights into the pathophysiology of childhood growth disorders and of the unrestrained growth of cancer. In addition, improved understanding of these growth-suppressing mechanisms may someday allow their therapeutic suspension in adult tissues to facilitate tissue regeneration.

From:
Endocr Rev. 2011 June; 32(3): 422–440.       Published online 2011 March 25. doi: 10.1210/er.2011-0001

Fig. 2.

Click on image to zoom

An external file that holds a picture, illustration, etc.<br /><br /><br />
Object name is zef0031127800002.jpg Object name is zef0031127800002.jpg

A complex growth-related genetic program occurs in multiple organs during juvenile life. A, Venn diagrams showing the number of genes down-regulated and up-regulated with age by microarray analysis in mouse and rats. The analysis included genes that showed age regulation (P < 0.05; ≥2.0-fold) in mouse kidney, lung, and heart or in both rat kidney and lung. The substantial overlap indicates that the program was highly conserved during the 20 million yr since the two species diverged. B, Heat maps based on the same set of genes. Each row corresponds to a single gene. Green, Down-regulation with age; red, up-regulation. Scale values are log2 (fold difference). C, A knockout phenotype was reported for 139 of the genes in this same gene set. For the down-regulated genes, knockout frequently resulted in decreased body size, suggesting that many down-regulated genes in this program are growth promoting. D, Bioinformatic analyses of these age-regulated genes using Ingenuity Pathway Analysis (IPA) 7.1 and GeneGO also suggest that many of the genes that are down-regulated with age serve to regulate proliferation. For IPA, the five most overrepresented molecular, cellular, or physiological functions are shown (solid barsP value; striped bars, number of significant genes involved). For GeneGO, all significant (P < 0.05) map folders are shown. [Reproduced from J. C. Lui et al.FASEB J 24:3083–3092, 2010 (113).]

From:
Endocr Rev. 2011 June; 32(3): 422–440.
Published online 2011 March 25. doi: 10.1210/er.2011-0001

Fig. 4.

Click on image to zoom

An external file that holds a picture, illustration, etc.<br /><br /><br />
Object name is zef0031127800004.jpg Object name is zef0031127800004.jpg

Model for a mechanism that restricts juvenile body growth. In early life, multiple growth-promoting genes are well expressed, leading to rapid growth. However, growth causes down-regulation of these growth-promoting genes (perhaps through epigenetic mechanisms) which causes growth to slow. Progression of this negative feedback loop would eventually cause the growth rate to approach zero.

From:
Endocr Rev. 2011 June; 32(3): 422–440.
Published online 2011 March 25. doi: 10.1210/er.2011-0001

Fig. 1.

Click on image to zoom

An external file that holds a picture, illustration, etc.<br /><br /><br />
Object name is zef0031127800001.jpg Object name is zef0031127800001.jpg

The decline in the human linear growth rate is not due to declining circulating IGF-I levels. First row, In humans, height increases rapidly in early childhood but eventually plateaus in adolescence (216). Second row, The linear growth velocity (first derivative of the height curve) decreases dramatically during infancy, more gradually during childhood, briefly rises during the pubertal growth spurt, and then resumes its decline, approaching zero (216). Third to fifth rows, As growth is slowing, there is a general increase in total IGF-I and IGFBP-3, both of which are stimulated by GH, as well as an increase in free IGF-I (derived from reference 52).